An observational study in Preeclampsia (PE) Risk and Oocyte Donation, sponsored by Universitair Ziekenhuis Brussel. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Universitair Ziekenhuis Brussel · Observational
The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.
882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.
This study's planned enrollment of 2,325 is above the median of 163 across 380 observational studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Universitair Ziekenhuis Brussel is the lead sponsor of 362 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated for oocyte donation at the Brussels IVF center.
Exclusion Criteria:
Patients who develop PE during their pregnancy after oocyte donation.
Patients who do not develop PE during their pregnancy after oocyte donation.
Preeclampsia development.
The development of PE throughout the pregnancy conceived through oocyte donation.
Time frame: From 20 weeks gestation until 6 weeks postpartum.
Development of early onset PE versus late onset PE.
The development of PE before 34 weeks gestation (= early onset PE) or after 34 weeks of gestation (= late onset PE).
Time frame: From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.
Preterm PE versus Term PE or PP PE
Development of preterm PE (\<37 weeks gestation), term PE (\>37 weeks gestation) and postpartum PE (after birth) throughout a pregnancy conceived through oocyte donation.
Time frame: From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.
Incidence of eclampsia, placental abruption, HELLP syndrome
The occurence of eclampsia, placental abruption and HELLP syndrome in pregnancies conceived through oocyte donation.
Time frame: From conception until 6 weeks postpartum in pregnancies conceived through oocyte donation.
Obstetrical complications
Incidence of obstetrical complications such as gestational hypertension, IUGR, PPROM, ...
Time frame: From conceptions until birth in pregnancies conceived through oocyte donation.
Delivery characteristics
Details about delivery such as preterm birth, the incidence and indication for caesarean sections, neonatal birth weights, neonatal birth defects, neonatal complications, ...
Time frame: From conception until birth in pregnancies conceived through oocyte donation.
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel